Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
CHILDREN'S ALLEGRA ALLERGY vs TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
1 tablet (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4 to 6 hours; maximum 4 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Triprolidine: 3-5 hours (terminal). Pseudoephedrine: 5-8 hours (terminal, pH-dependent; urine pH 8: ~13 hours, pH 5: ~3 hours). Clinical: normal renal function.
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Triprolidine: ~80% renal (mostly metabolites, <5% unchanged). Pseudoephedrine: ~70-90% renal (43-96% unchanged, depends on urine pH; acidic urine increases elimination, alkaline decreases). Biliary/fecal: negligible for both.
Category C
Category A/B
Antihistamine
Antihistamine